| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
PHARMACOKINETICS AND PHARMACODYNAMICS |
From Cardiovascular Projects, Research Centre, Orion Pharma, Espoo, Finland (Dr Põder, Dr Sundberg, Dr Antila, S Rantanen); Mustamäe Hospital, Tallinn, Estonia (Dr Eha, Dr Heinpalu, Dr Loogna, Dr Planken); and Department of Clinical Pharmacology, Helsinki University Central Hospital, Finland (Dr Lehtonen).
The objective of this study was to explore the pharmacodynamics and pharmacokinetics of oral levosimendan in patients with severe congestive heart failure. This was a randomized, parallel-group, double-blind, placebo-controlled trial. Oral levosimendan 2 to 8 mg daily or placebo was administered to 25 patients with New York Heart Association class III-IV congestive heart failure for 4 weeks. Pharmacodynamic variables consisted of heart rate-corrected electromechanical systole, heart rate, and systolic and diastolic blood pressure. The pharmacokinetics of levosimendan and its metabolites, OR-1855 and OR-1896, was assessed. The 4- to 8-mg daily doses of oral levosimendan showed moderate inotropic effects. Blood pressure remained unchanged with all doses. A moderate increase in heart rate was observed except with the 2-mg dose. Pharmacokinetic parameters of the metabolites increased linearly with the dose (P 
.002 for Cmax and AUC0-8h for both treatment groups). It was concluded that oral levosimendan has inotropic and chronotropic effects in patients with severe congestive heart failure. Plasma concentrations of its metabolites increase dose dependently.
Key Words: Levosimendan • OR-1855 • OR-1896 • pharmacokinetics • pharmacodynamics • congestive heart failure (CHF)
Address for reprints: Pentti Põder, MD, Cardiovascular Projects, Research Centre, Orion Pharma, PO Box 65, Fin-02101 Espoo, Finland.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Kota, A. S. Prasad, C. Economides, and B. N. Singh Levosimendan and Calcium Sensitization of the Contractile Proteins in Cardiac Muscle: Impact on Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2008; 13(4): 269 - 278. [Abstract] [PDF]
|
|
|
|
 |
|
 M. S. Nieminen, J. G.F. Cleland, J. Eha, Y. Belenkov, M. Kivikko, P. Poder, and T. Sarapohja Oral levosimendan in patients with severe chronic heart failure--The PERSIST study Eur J Heart Fail, December 1, 2008; 10(12): 1246 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Meyer, R. C. Klocke, J. D. Schipke, E. Gams, and B. Korbmacher Ca(2+) sensitizer superior to catecholamine during myocardial stunning? Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 326 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masutani, H.-J. Cheng, M. Hyttila-Hopponen, J. Levijoki, A. Heikkila, A. Vuorela, W. C. Little, and C.-P. Cheng Orally Available Levosimendan Dose-Related Positive Inotropic and Lusitropic Effect in Conscious Chronically Instrumented Normal and Heart Failure Dogs J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 236 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Raja and B. S. Rayen Levosimendan in Cardiac Surgery: Current Best Available Evidence Ann. Thorac. Surg., April 1, 2006; 81(4): 1536 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Parissis, D. Farmakis, and D. T. Kremastinos Levosimendan therapy in decompensated chronic heart failure: Favourable haemodynamic and neurohormonal effects but for how long? Eur J Heart Fail, March 1, 2006; 8(2): 215 - 215. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dernellis and M. Panaretou Effects of Levosimendan on Restrictive Left Ventricular Filling in Severe Heart Failure: A Combined Hemodynamic and Doppler Echocardiographic Study Chest, October 1, 2005; 128(4): 2633 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, and J. J. Ferrer-Hita Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST-Elevation Myocardial Infarction: A Series of Cases J. Clin. Pharmacol., June 1, 2005; 45(6): 704 - 708. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
